Neovacs SA (FR:ALNEV) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neovacs SA has announced a modest fundraising effort of €0.2M through the issuance of OCEANE-BSA to finance its allergy research program, Kinoïde®, and to invest in promising BioTech and MedTech projects. The recent fundraising contributes to a total of €25.9M raised to date, which may lead to significant dilution for current shareholders, reducing a 1% stake to less than 0.21%. Investors are cautioned about the potential risk of capital loss and the dilutive impact of such financial operations.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.